These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 18055977

  • 1. High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma.
    van der Spek E, Bloem AC, Sinnige HA, Lokhorst HM.
    Haematologica; 2007 Dec; 92(12):e130-1. PubMed ID: 18055977
    [Abstract] [Full Text] [Related]

  • 2. Treatment of refractory multiple myeloma with vincristine, adriamycin, dexamethasone, and with repeated application of cyclophosphamide (C-VAD).
    Adam Z, Elbl L, Vorlicek J, Hájek R, Hájek D, Hejlová N, Králová E, Novotná H.
    Acta Med Austriaca; 1994 Dec; 21(4):111-5. PubMed ID: 7871966
    [Abstract] [Full Text] [Related]

  • 3. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D, Bosković D, Radosević N, Elezović I, Tomin D, Gotić M, Antunović P.
    Srp Arh Celok Lek; 1996 Dec; 124(11-12):292-6. PubMed ID: 9132962
    [Abstract] [Full Text] [Related]

  • 4. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma.
    Segeren CM, Sonneveld P, van der Holt B, Baars JW, Biesma DH, Cornellissen JJ, Croockewit AJ, Dekker AW, Fibbe WE, Löwenberg B, van Marwijk Kooy M, van Oers MH, Richel DJ, Schouten HC, Vellenga E, Verhoef GE, Wijermans PW, Wittebol S, Lokhorst HM.
    Br J Haematol; 1999 Apr; 105(1):127-30. PubMed ID: 10233375
    [Abstract] [Full Text] [Related]

  • 5. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
    Hussein MA, Wood L, Hsi E, Srkalovic G, Karam M, Elson P, Bukowski RM.
    Cancer; 2002 Nov 15; 95(10):2160-8. PubMed ID: 12412170
    [Abstract] [Full Text] [Related]

  • 6. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial.
    Rifkin RM, Gregory SA, Mohrbacher A, Hussein MA.
    Cancer; 2006 Feb 15; 106(4):848-58. PubMed ID: 16404741
    [Abstract] [Full Text] [Related]

  • 7. A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma.
    Cook G, Clark RE, Morris TC, Robertson M, Lucie NP, Anderson S, Paul J, Franklin IM.
    Br J Haematol; 2004 Sep 15; 126(6):792-8. PubMed ID: 15352982
    [Abstract] [Full Text] [Related]

  • 8. [Lower cardiotoxicity of adriamycin during continuous administration in patients with refractory multiple myeloma treated with cyclophosphamide, vincristine, adriamycin and dexamethasone (C-VAD)].
    Adam Z, Elbl L, Vorlícek J, Hájek R, Tomíska M, Hejlová N, Králová E, Novotná H.
    Vnitr Lek; 1994 Aug 15; 40(8):506-12. PubMed ID: 7941437
    [Abstract] [Full Text] [Related]

  • 9. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
    Sonneveld P, Marie JP, Huisman C, Vekhoff A, Schoester M, Faussat AM, van Kapel J, Groenewegen A, Charnick S, Zittoun R, Löwenberg B.
    Leukemia; 1996 Nov 15; 10(11):1741-50. PubMed ID: 8892677
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma.
    Corso A, Barbarano L, Zappasodi P, Cairoli R, Alessandrino EP, Mangiacavalli S, Ferrari D, Fava S, Fiumanò M, Frigerio G, Isa L, Luraschi A, Klersy C, De Paoli A, Vergani C, Banfi L, Perego D, Ucci G, Pinotti G, Savarè M, Uziel L, Vismara A, Morra E, Lazzarino M.
    Haematologica; 2004 Sep 15; 89(9):1124-7. PubMed ID: 15377474
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.
    Dadacaridou M, Papanicolaou X, Maltesas D, Megalakaki C, Patos P, Panteli K, Repousis P, Mitsouli-Mentzikof C.
    J BUON; 2007 Sep 15; 12(1):41-4. PubMed ID: 17436400
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Chemotherapy of resistant multiple myeloma with vincristine, adriamycin and dexamethasone (VAD).
    Maniatis A, Stamatellou M, Papanastasiou K.
    Chemioterapia; 1987 Jun 15; 6(2 Suppl):727-8. PubMed ID: 3509532
    [No Abstract] [Full Text] [Related]

  • 18. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
    Luo SK, Li J, Hong WD, Zhao Y, Tong XZ.
    Ai Zheng; 2005 Dec 15; 24(12):1518-21. PubMed ID: 16351805
    [Abstract] [Full Text] [Related]

  • 19. Effective treatment of advanced multiple myeloma refractory to alkylating agents.
    Barlogie B, Smith L, Alexanian R.
    N Engl J Med; 1984 May 24; 310(21):1353-6. PubMed ID: 6546971
    [Abstract] [Full Text] [Related]

  • 20. High early mortality rate in elderly patients with multiple myeloma receiving a vincristine-doxorubicin-dexamethasone regimen.
    Teng HW, Teng CJ, Wang WS, Chen PM, Chiou TJ, Hsu HC, Liu JH, Yen CC, Hsiao LT, Yang MH, Chao TC, Yang YH, Gau JP.
    Am J Hematol; 2010 Oct 24; 85(10):812-5. PubMed ID: 20734459
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.